Immunomodulatory effects of radiation: What is next for cancer therapy?

Future Oncology

Volumn 12, Issue 2, 2016, Pages 239-256

  Kumari, Anita ^a   Simon, Samantha S ^a   Moody, Tomika D ^a   Garnett Benson, Charlie ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Cancer; Cytotoxic cells; Immunogenic modulation; Immunotherapy; Low dose radiotherapy; Radiation; Single dose radiotherapy; T cells

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA;

ANTIGEN RECOGNITION; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CYTOTOXIC T LYMPHOCYTE; EPIGENETICS; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LOW ENERGY RADIATION; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; T LYMPHOCYTE; TUMOR CELL; ANIMAL; CYTOLOGY; DRUG EFFECTS; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; IONIZING RADIATION; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PHYSIOLOGY; RADIATION RESPONSE; RADIOTHERAPY DOSAGE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; COMBINED MODALITY THERAPY; HUMANS; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASMS; RADIATION, IONIZING; RADIOTHERAPY DOSAGE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84962629239     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.300     Document Type: Review

References (112)

1. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl Cancer Inst. 105(4), 256-265 (2013).
2. Panaretakis T, Kepp O, Brockmeier U et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 28(5), 578-590 (2009).
3. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Ann. Rev. Immunol. 31, 51-72 (2013).
4. Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int. J. Mol. Sci. 15(1), 927-943 (2014).
5. Golden EB, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC. The convergence of radiation and immunogenic cell death signaling pathways. Front. Oncol. 2, 88 (2012).
6. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 68(11), 4026-4030 (2008).
7. Tesniere A, Panaretakis T, Kepp O et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15(1), 3-12 (2008).
8. Hodge JW, Kwilas A, Ardiani A, Gameiro SR. Attacking malignant cells that survive therapy: exploiting immunogenic modulation. Oncoimmunology 2(12), e26937 (2013).
9. Wittenberg MM, Fahim A, Ahmed MM, Hodge JW. Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiat. Res. 182(2), 126-138 (2014).
10. Shahabi V, Postow MA, Tuck D, Wolchok JD. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am. J. Clin. Oncol. 38(1), 90-97 (2015).
11. Sharabi AB, Tran PT, Lim M, Drake CG, Deweese TL. Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park) 29(5), 331-340 (2015).
12. Postow MA, Callahan MK, Barker CA et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366(10), 925-931 (2012).
13. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int. J. Radiat. Oncol. Biol. Phys. 85(2), 293-295 (2013).
14. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res. 1(6), 365-372 (2013)., This was the first study to administer local radiotherapy (RT) to a metastatic lesion in a treatment-refractory lung cancer patient with the intent to induce an abscopal response.
15. Golden EB, Chhabra A, Chachoua A et al. Local radiotherapy and granulocytemacrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 16(7), 795-803 (2015).
16. Hiniker SM, Chen DS, Reddy S et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl. Oncol. 5(6), 404-407 (2012).
17. Garnett-Benson C, Hodge JW, Gameiro SR. Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. Semin. Radiat. Oncol. 25(1), 46-53 (2015).
18. Disis ML. Mechanism of action of immunotherapy. Semin. Oncol. 41(Suppl. 5), S3-S13 (2014).
19. Makinde AY, John-Aryankalayil M, Palayoor ST, Cerna D, Coleman CN. Radiation survivors: understanding and exploiting the phenotype following fractionated radiation therapy. Mol. Cancer Res. 11(1), 5-12 (2013).
20. Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front. Oncol. 2, 153 (2012).
21. Reits EA, Hodge JW, Herberts CA et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203(5), 1259-1271 (2006)., This report demonstrated enhanced translation due to activation of the mTOR pathway that resulted in increased peptide production, antigen presentation and cytotoxic T lymphocyte (CTL) recognition of irradiated cells.
22. Liao YP, Wang CC, Butterfield LH et al. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J. Immunol. 173(4), 2462-2469 (2004).
23. Sharma A, Bode B, Wenger RH et al. Gamma-radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS ONE 6(11), e28217 (2011).
24. Gasser S, Raulet DH. Activation and self-tolerance of natural killer cells. Immunol. Rev. 214, 130-142 (2006).
25. Liu C, Suksanpaisan L, Chen YW, Russell SJ, Peng KW. Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp. Hematol. 41(6), 508-517 (2013).
26. Sheard MA, Krammer PH, Zaloudik J. Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95. Br. J. Cancer 80(11), 1689-1696 (1999).
27. Abdulkarim B, Sabri S, Deutsch E et al. Radiation-induced expression of functional Fas ligand in EBV-positive human nasopharyngeal carcinoma cells. Int. J. Cancer 86(2), 229-237 (2000).
28. Trott KR. Therapeutic effects of low radiation doses. Strahlenther. Onkol. 170(1), 1-12 (1994).
29. Hildebrandt G, Seed MP, Freemantle CN, Alam CA, Colville-Nash PR, Trott KR. Mechanisms of the anti-inflammatory activity of low-dose radiation therapy. Int. J. Radiat. Biol. 74(3), 367-378 (1998).
30. Hellweg CE. The Nuclear Factor kappaB pathway: a link to the immune system in the radiation response. Cancer Lett. doi:10.1016/j. canlet.02.019 (2015) (Epub ahead of print).
31. Pore N, Gupta AK, Cerniglia GJ et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res. 66(18), 9252-9259 (2006).
32. Yang G, Kong Q, Wang G et al. Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy. Cancer Biother. Radiopharm. 29(10), 428-434 (2014).
33. Ren H, Shen J, Tomiyama-Miyaji C et al. Augmentation of innate immunity by low-dose irradiation. Cell Immunol. 244(1), 50-56 (2006).
34. Klug F, Prakash H, Huber PE et al. Low-dose irradiation programs macrophage differentiation to an iNOS (+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24(5), 589-602 (2013).
35. Lodermann B, Wunderlich R, Frey S et al. Low dose ionising radiation leads to a NF-kappaB dependent decreased secretion of active IL-lbeta by activated macrophages with a discontinuous dose-dependency. Int. J. Radiat. Biol. 88(10), 727-734 (2012).
36. Wunderlich R, Ernst A, Rodel F et al. Low and moderate doses of ionizing radiation up to 2Gy modulate transmigration and chemotaxis of activated macrophages, provoke an anti-inflammatory cytokine milieu, but do not impact upon viability and phagocytic function. Clin. Exp. Immunol. 179(1), 50-61 (2015).
37. Liu SZ, Jin SZ, Liu XD, Sun YM. Role of CD28/B7 costimulation and IL-12/IL-10 interaction in the radiation-induced immune changes. BMC Immunol. 2, 8 (2001).
38. Shigematsu A, Adachi Y, Koike-Kiriyama N et al. Effects of low-dose irradiation on enhancement of immunity by dendritic cells. J. Radiat. Res. 48(1), 51-55 (2007).
39. Wang B, Li B, Dai Z et al. Low-dose splenic radiation inhibits liver tumor development of rats through functional changes in CD4 + CD25+Treg cells. Int. J. Biochem. Cell Biol. 55, 98-108 (2014).
40. Farooque A, Mathur R, Verma A et al. Low-dose radiation therapy of cancer: role of immune enhancement. Expert Rev. Anticancer Ther. 11(5), 791-802 (2011).
41. Sanfilippo NJ, Cooper BT. Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations. Am. J. Clin. Exp. Urol. 2(4), 286-293 (2014).
42. Mangoni M, Desideri I, Detti B et al. Hypofractionation in prostate cancer: radiobiological basis and clinical appliance. Biomed. Res. Int. 2014, 781340 (2014).
43. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. L ocal radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174(12), 7516-7523 (2005).
44. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 64(21), 7985-7994 (2004)., This report demonstrated that a panel of human tumor cells, including some with defective Fas signaling, was more sensitive to lysis by CTLs after single dose RT.
45. Newcomb EW, Demaria S, Lukyanov Y et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin. Cancer Res. 12(15), 4730-4737 (2006).
46. Chakraborty M, Wansley EK, Carrasquillo JA et al. The use of chelated radionuclide (samarium-153-ethylenediaminetetramethyle nephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin. Cancer Res. 14(13), 4241-4249 (2008).
47. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiationinduced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 5(2), 403-416 (2014)., This is the first paper to report that RT-induced CALR expression could enhanced CTL cytolysis of tumor cells and suggests an antigen-presenting cell-independent role for CALR.
48. Kumari A, Cacan E, Greer SF, Garnett-Benson C. Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells. J. Immunother. Cancer 1, 17 (2013)., This report demonstrates that irradiated tumor cells are not passive targets, and can alter the biology of responding effector T cells by modulating expression of proteins that enhance T-cell activation and survival.
49. Bernstein MB, Garnett CT, Zhang H et al. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother. Radiopharm. 29(4), 153-161 (2014).
50. Deng L, Liang H, Burnette B, Weicheslbaum RR, Fu YX. Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. Oncoimmunology 3, e28499 (2014).
51. Aryankalayil MJ, Makinde AY, Gameiro SR et al. Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells. Radiat. Res. 182(2), 139-148 (2014).
52. Gelbard A, Garnett CT, Abrams SI et al. Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin. Cancer Res. 12(6), 1897-1905 (2006).
53. Ruocco MG, Pilones KA, Kawashima N et al. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J. Clin. Invest. 122(10), 3718-3730 (2012).
54. Behrends U, Peter RU, Hintermeier-Knabe R et al. Ionizing radiation induces human intercellular adhesion molecule-1 in vitro. J. Invest. Dermatol. 103(5), 726-730 (1994).
55. Kim JY, Son YO, Park SW et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp. Mol. Med. 38(5), 474-484 (2006).
56. Chakraborty M, Abrams SI, Camphausen K et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol. 170(12), 6338-6347 (2003)., This was the first report of the direct ability of in vivo RT to modulate expression of a gene that directly enhanced tumor cell susceptibility to cytolysis by CTLs.
57. Sheard MA, Vojtesek B, Janakova L, Kovarik J, Zaloudik J. Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int. J. Cancer 73(5), 757-762 (1997).
58. Rigberg DA, Centeno J, Kim FS et al. Irradiation-induced up-regulation of Fas in esophageal squamous cell carcinoma is not accompanied by Fas ligand-mediated apoptosis. J. Surg. Oncol. 71(2), 91-96 (1999).
59. Ifeadi V, Garnett-Benson C. Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways. PLoS ONE 7(2), e31762 (2012).
60. Marini P, Schmid A, Jendrossek V et al. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 5, 5 (2005).
61. Wu CT, Hsieh CC, Yen TC, Chen WC, Chen MF. TGF-beta1 mediates the radiation response of prostate cancer. J. Mol. Med. 93(1), 73-82 (2015).
62. Zhang JS, Nakatsugawa S, Niwa O, Ju GZ, Liu SZ. Ionizing radiation-induced IL-1 alpha, IL-6 and GM-CSF production by human lung cancer cells. Chin. Med. J. 107(9), 653-657 (1994).
63. Hallahan DE, Spriggs DR, Beckett MA, Kufe DW, Weichselbaum RR. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc. Natl Acad. Sa. USA 86(24), 10104-10107 (1989).
64. Matsumura S, Wang B, Kawashima N et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J. Immunol. 181(5), 3099-3107 (2008)., This report initiated the present concept of immunogenic modulation of tumors by demonstrating that irradiated tumors could express proteins that would enhance recruitment and activities of effector T cells in irradiated tumors.
65. Draghiciu O, Walczak M, Hoogeboom BN et al. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. Int. J. Cancer 134(4), 859-872 (2014).
66. Huang J, Wang QJ, Yang S et al. Irradiation enhances human T-cell function by upregulating CD70 expression on antigenpresenting cells in vitro. J. Immunother. 34(4), 327-335 (2011).
67. Gupta A, Probst HC, Vuong V et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J. Immunol. 189(2), 558-566 (2012).
68. Parker JJ, Jones JC, Strober S, Knox SJ. Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. Clm. Immunol. 148(1), 44-55 (2013).
69. Cao M, Cabrera R, Xu Y, Liu C, Nelson D. Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells. Cell Biol. Int. 33(5), 565-571 (2009).
70. Tsai CS, Chen FH, Wang CC et al. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int. J. Radiat. Oncol. Biol. Phys. 68(2), 499-507 (2007).
71. Kober J, Leitner J, Klauser C et al. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur. J. Immunol. 38(10), 2678-2688 (2008).
72. Verneris MR, Karimi M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 103(8), 3065-3072 (2004).
73. Niyazi M, Marini P, Daniel PT, Humphreys R, Jendrossek V, Belka C. Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin. Oncol. Rep. 21(6), 1455-1460 (2009).
74. Verbrugge I, Wissink EH, Rooswinkel RW et al. Combining radiotherapy with APO010 in cancer treatment. Clin. Cancer Res. 15(6), 2031-2038 (2009).
75. Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 22(37), 5813-5827 (2003).
76. Bae JH, Kim JG, Heo K, Yang K, Kim TO, Yi JM. Identification of radiation-induced aberrant hypomethylation in colon cancer. BMC Genomics 16, 56 (2015).
77. Cacan E, Greer SF, Garnett-Benson C. Radiation-induced modulation of immunogenic genes in tumor cells is regulated by both histone deacetylases and DNA methyltransferases. Int. J. Oncol. doi:10.3892/ijo.3192 (2015) (Epub ahead of print).
78. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 148(6), 1172-1187 (2012).
79. Simone NL, Soule BP, Ly D et al. Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS ONE 4(7), e6377 (2009).
80. Palayoor ST, John-Aryankalayil M, Makinde AY, Falduto MT, Magnuson SR, Coleman CN. Differential expression of stress and immune response pathway transcripts and miRNAs in normal human endothelial cells subjected to fractionated or single-dose radiation. Mol. Cancer Res. 12(7), 1002-1015 (2014).
81. Goans RE, Waselenko JK. Medical management of radiological casualties. Health Physics 89(5), 505-512 (2005).
82. Fehervari Z, Sakaguchi S. A paragon of self-tolerance: CD25 + CD4 + regulatory T cells and the control of immune responses. Arthritis Res. Ther. 6(1), 19-25 (2004).
83. Woo EY, Chu CS, Goletz TJ et al. Regulatory CD4 + CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61(12), 4766-4772 (2001).
84. Ling KL, Pratap SE, Bates GJ et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun. 7, 7 (2007).
85. Deng L, Liang H, Burnette B et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124(2), 687-695 (2014).
86. Xu J, Escamilla J, Mok S et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 73(9), 2782-2794 (2013).
87. Crittenden MR, Savage T, Cottam B et al. The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor. PLoS ONE 8(7), e69527 (2013).
88. Halpern JN, Cohen E, Mekori T et al. The effect of in vitro irradiation on human NK cell activity. A preliminary report. J. Med. 22(4-5), 243-254 (1991).
89. Nakagawa K, Yoshida F, Omori N, Tsunoda T, Nose T. The effect of radiation therapy combined with natural killer cells against spontaneous murine fibrosarcoma. Biotherapy 2(1), 69-75 (1990).
90. Sonn CH, Choi JR, Kim TJ et al. Augmentation of natural cytotoxicity by chronic low-dose ionizing radiation in murine natural killer cells primed by IL-2. J. Radiat. Res. 53(6), 823-829 (2012).
91. Zarcone D, Tilden AB, Lane VG, Grossi CE. Radiation sensitivity of resting and activated nonspecific cytotoxic cells of T lineage and NK lineage. Blood 73(6), 1615-1621 (1989).
92. Mizutani Y, Uchida A, Fujimoto T, Ikenaga M, Yoshida O. Enhancement by x-ray irradiation of target cell susceptibility to natural killer cells. Immunol. Lett. 22(3), 247-251 (1989).
93. Uchida A, Mizutani Y, Nagamuta M, Ikenaga M. Effects of x-ray irradiation on natural killer (NK) cell system. I. Elevation of sensitivity of tumor cells and lytic function of NK cells. Immunopharmacol. Immunotoxicol. 11(2-3), 507-519 (1989).
94. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64(12), 4328-4337 (2004).
95. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J. Immunol. 180(5), 3132-3139 (2008).
96. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J. Exp. Med. 209(13), 2351-2365 (2012).
97. Pinel MI, Esteves EB, Rumjanek VM. Increased natural killer cell activity in uterine cervix cancer patients undergoing radiation therapy. Nat. Immun. 14(4), 216-224 (1995).
98. Zhang B, Bowerman NA, Salama JK et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204(1), 49-55 (2007).
99. Lim JY, Gerber SA, Murphy SP, Lord EM. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8 + T cells. Cancer Immunol. Immunother. 63(3), 259-271 (2014).
100. Wei S, Egenti MU, Teitz-Tennenbaum S, Zou W, Chang AE. Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice. J. Immunother. 36(2), 124-132 (2013).
101. Hodge JW, Sharp HJ, Gameiro SR. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother. Radiopharm. 27(1), 12-22 (2012)., This study demonstrated that sublethal radiation doses could modulate tumor phenotype and induce T-cell responses to tumor antigens not encoded by a therapeutic vaccine (antigen cascade), and that the antigen cascade could mediate abscopal tumor regression of an antigen disparate tumor in vivo.
102. Demaria S, Ng B, Devitt ML et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 862-870 (2004).
103. Victor CT, Rech AJ, Maity A et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature doi:10.1038/nature14292 (2015) (Epub ahead of print).
104. Lee SJ, Myers L, Muralimohan G et al. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J. Immunol. 173(5), 3002-3012 (2004).
105. Redmond WL, Gough MJ, Weinberg AD. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur. J. Immunol. 39(8), 2184-2194 (2009).
106. Cao ZA, Daniel D, Hanahan D. Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2, 11 (2002).
107. Liang H, Deng L, Burnette B, Weichselbaum RR, Fu YX. Radiation-induced tumor dormancy reflects an equilibrium between the proliferation and T lymphocyte-mediated death of malignant cells. Oncoimmunology 2(9), e25668 (2013).
108. Gandhi SJ, Minn A, Vonderheide RH, Wherry EJ, Hahn SM, Maity A. Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett. doi:10.1016/j. canlet.03.024 (2015) (Epub ahead of print).
109. Chi KH, Wang YS, Kao SJ. Improving radioresponse through modification of the tumor immunological microenvironment. Cancer Biother. Radiopharm. 27(1), 6-11 (2012).
110. Gough MJ, Young K, Crittenden M. The impact of the myeloid response to radiation therapy. Clin. Dev. Immunol. 2013, 281958 (2013).
111. Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC. Combinations of immunotherapy and radiation in cancer therapy. Front. Oncol. 4, 325 (2014).
112. Chiriva-Internati M, Grizzi F, Pinkston J et al. Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev. Biol. Anim. 42(3-4), 89-95 (2006).